BioVie (BIVI)
NASDAQ:BIVI
Want to see BIVI full AI Analyst Report?
BIVI Stock Chart & Stats
$1.56
-$0.21(-8.50%)
At close: 4:00 PM EST
$1.56
-$0.21(-8.50%)
Day’s Range― - ―
52-Week Range$1.06 - $12.10
Previous CloseN/A
Volume1.62M
Average Volume (3M)240.84K
Market Cap
$12.59M
Enterprise Value-$2.09M
Total Cash (Recent Filing)$13.10M
Total Debt (Recent Filing)$295.72K
Price to Earnings (P/E)―
Beta1.66
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.47
Shares Outstanding7,541,839
10 Day Avg. Volume205,264
30 Day Avg. Volume240,835
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.72
Price to Sales (P/S)0.00
P/FCF Ratio-0.72
Enterprise Value/Market Cap-0.17
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit9.13
Enterprise Value/Ebitda0.10
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering0
EPS Forecast (FY)-2.95
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Equity PositionA strong equity position with minimal debt provides financial stability, allowing BioVie to fund R&D activities without immediate pressure from creditors.
Innovative Product PipelineBioVie's focus on innovative therapies for unmet medical needs positions it well for future growth, as successful trials could lead to significant market opportunities.
Partnership OpportunitiesStrategic partnerships can provide funding and expertise, accelerating product development and commercialization, which is vital for a clinical-stage biotech company.
Bears Say
High Cash BurnHigh cash burn without revenue generation can strain financial resources, necessitating continuous external financing, which may dilute shareholder value over time.
No Revenue GenerationThe absence of revenue generation limits financial flexibility and increases reliance on external funding, posing risks if product development timelines extend.
Ongoing Net LossesOngoing net losses reflect the challenges of sustaining operations without revenue, highlighting the need for successful product commercialization to achieve profitability.
BioVie News
BIVI FAQ
What was BioVie’s price range in the past 12 months?
BioVie lowest stock price was $1.06 and its highest was $12.10 in the past 12 months.
What is BioVie’s market cap?
BioVie’s market cap is $12.59M.
When is BioVie’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were BioVie’s earnings last quarter?
BioVie released its earnings results on Feb 14, 2024. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.275 by $0.055.
Is BioVie overvalued?
According to Wall Street analysts BioVie’s price is currently Overvalued.
Does BioVie pay dividends?
BioVie does not currently pay dividends.
What is BioVie’s EPS estimate?
BioVie’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioVie have?
BioVie has 7,541,839 shares outstanding.
What happened to BioVie’s price movement after its last earnings report?
BioVie reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.275. Following the earnings report the stock price went down -0.761%.
Which hedge fund is a major shareholder of BioVie?
Currently, no hedge funds are holding shares in BIVI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioVie
BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis. Additionally, BioVie is advancing NE3107, which is currently undergoing a Phase III clinical trial for the management of mild to moderate Alzheimer's disease, and is also in a Phase I clinical trial for the treatment of Parkinson's disease. Further preclinical investigations are underway for NE3107, exploring its potential applications in treating multiple myeloma and prostate cancer. Established in 2013, the company adopted its current name, BioVie Inc., in July 2016, having previously operated as NanoAntibiotics, Inc. Its corporate headquarters are situated in Carson City, Nevada.
Technical Analysis
Ownership Overview
13.88% Insiders
3.07% Mutual Funds
7.12% Other Institutional Investors
74.98% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---